Viewing Study NCT00426933


Ignite Creation Date: 2025-12-25 @ 3:00 AM
Ignite Modification Date: 2026-02-27 @ 7:55 PM
Study NCT ID: NCT00426933
Status: COMPLETED
Last Update Posted: 2010-09-14
First Post: 2007-01-23
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 2 Safety and Efficacy Study of Daptomycin in Complicated Skin and Skin Structure Infections
Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Soft Tissue Infections View
Keywords:

Keywords

Keyword Brief Keyword Text View
None cSSSI View
None MRSA View